Clindacyl 75 mg Tablets for dogs

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Clindamycin

Available from:

Vetoquinol UK Limited

ATC code:

QJ01FF01

INN (International Name):

Clindamycin

Dosage:

75 mg/tablet

Pharmaceutical form:

Tablet

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Dogs

Therapeutic area:

clindamycin

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

2000-09-01

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clindacyl 75 mg Tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE
Clindamycin
75 mg
(as Clindamycin Hydrochloride)
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
A round white tablet with a breakline on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clindacyl 75 mg Tablets are antibiotics indicated for the treatment of
infected wounds, abscesses, pyoderma and oral
cavity/dental infections caused by or associated with
clindamycin-sensitive staphylococci, streptococci, pneumococci,
bacteroidaceae,_ Fusobacterium necrophorum, Clostridium perfringens_
and osteomyelitis caused by_ Staphylococcus_
_aureus_.
Clindacyl 75 mg Tablets can also be used to help provide antimicrobial
cover during dental procedures.
4.3 CONTRAINDICATIONS
Do not administer to animals with hypersensitivity to clindamycin and
lincomycin preparations.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_0_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_1_
_C_
_R_
_N_
_ _
_7_
_0_
_0_
_7_
_9_
_1_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE
During prolonged osteomyelitis therapy of one month or greater,
periodic liver and kidney function tests and blood
counts should be performed.
Patients with severe renal and/or very severe he